Pure Global AI
NCT06326437Not yet recruiting

Dyadic Intervention for Psychological Distress of Patients With Colorectal Cancer and Their Spouses

The Effect of Dyadic Intervention on Psychological Distress of Young and Middle-aged Patients With Colorectal Cancer and Their Spouses: a Feasibility Study
Sun Yat-sen UniversityClinicalTrials.govother
Verified
Study focus
Disease/Condition
Colorectal Cancer
Drug/Device/Intervention
6-week dyadic intervention
Study type
Interventional
Intervention type
other
Sponsor & location
Primary sponsor
Sun Yat-sen University
Location
Guangzhou, China
Timeline & enrollment
Phase
N/A
Start date
Apr 01, 2024
End date
Jul 01, 2024
Enrollment
30 participants
Primary outcome

the Kessler psychological distress scale-10

Summary

The overall aim of the study is to evaluate the preliminary effect and feasibility of a
 dyadic intervention on mutuality, psychological strengths (i.e., illness cognition and dyadic
 coping), psychological distress, and QoL outcomes of patients with colorectal cancer and
 spouses. The colorectal cancer couples will be randomly allocated to the intervention group
 to receive a 6-week dyadic intervention, or to the control group to receive the usual care
 provided by the clinical team in the hospital.

ICD-10 classifications
Malignant neoplasm of colonMalignant neoplasm: Descending colonMalignant neoplasm: Colon, unspecifiedMalignant neoplasm: Ascending colonMalignant neoplasm: Overlapping lesion of colon
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06326437
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06326437 through Pure Global AI's free database. This phase not specified trial is sponsored by Sun Yat-sen University and is currently Not yet recruiting. The study focuses on Colorectal Cancer. Target enrollment is 30 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.